Parkinson's Disease Tulip


advertisement
 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 01-23-2008, 08:36 PM #1
ZucchiniFlower's Avatar
ZucchiniFlower ZucchiniFlower is offline
Member
 
Join Date: Sep 2006
Posts: 782
15 yr Member
ZucchiniFlower ZucchiniFlower is offline
Member
ZucchiniFlower's Avatar
 
Join Date: Sep 2006
Posts: 782
15 yr Member
Default Neurodegenerative disorders: Normalizing Parkinsonian networks

Nature Reviews Neuroscience 9, 7 (January 2008) | doi:10.1038/nrn2306

Neurodegenerative disorders: Normalizing Parkinsonian networks

Leonie Welberg

Gene therapy for the treatment of the motor symptoms of Parkinson's disease is in an early stage of development. Earlier this year, Eidelberg and colleagues published the initial results of a therapy involving gene delivery directly to the subthalamic nucleus (STN), which improved the patients' motor function. They now show that this treatment also normalized metabolic changes associated with Parkinson's disease that occur in a network that drives motor activity, providing an objective measure of treatment outcome.

Patients with Parkinson's disease have abnormal metabolic activity — which can be measured using [18F]-fluorodeoxyglucose positron emission tomography — both in individual brain regions and in two separate networks, one consisting of regions associated with motor functioning and the other of areas involved in cognition. Here, the authors assessed whether the gene therapy normalized metabolic activity in the patients' brains.

The therapy involved unilateral infusion into the STN of a viral vector containing the gene for glutamic acid decarboxylase (GAD), which catalyzes the decarboxylation of glutamate to GABA (gamma-aminobutyric acid) and thus reduces glutamatergic neurotransmission in the basal ganglia. The authors measured glucose metabolism in the patients' brains at baseline and 6 and 12 months after surgery.

They showed that the gene therapy altered regional glucose metabolism in the operated hemisphere only, with reductions in the thalamus but increases in the primary motor area and the premotor cortex at both time points.

Network activity was also changed by the gene therapy: the elevation in activity of the motor-associated network that is associated with Parkinson's disease was reduced in the treated hemisphere but not in the untreated hemisphere at 6 and 12 months after gene therapy. Importantly, the decline in network activity correlated with improvement in motor functioning. By contrast, the treatment had no effect on the elevated activity of the cognition-associated network in either hemisphere.

These findings indicate that GAD gene therapy affects both regional and network metabolic activity in patients with Parkinson's disease, in brain areas that are associated with motor function but not in areas involved in cognition. Moreover, they suggest that measurements of activity in metabolic networks can be used to objectively assess the effectiveness of potential new treatments for Parkinson's disease.
ZucchiniFlower is offline   Reply With QuoteReply With Quote
 


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
B Vitamins and Berries and Age-Related Neurodegenerative Disorders Stitcher Parkinson's Disease 1 11-11-2007 10:49 AM
Mechanical stress and formation of protein aggregates in neurodegenerative disorders BobbyB ALS News & Research 0 11-03-2007 06:37 AM
Two Distinct Parkinson's Networks Identified ZucchiniFlower Parkinson's Disease 6 07-13-2007 09:57 PM
Team reports genetic link between aging, neurodegenerative disorders BobbyB ALS News & Research 0 07-09-2007 08:37 PM


All times are GMT -5. The time now is 06:50 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.